共查询到19条相似文献,搜索用时 625 毫秒
1.
HPLC法测定微乳中伊维菌素的含量 总被引:4,自引:1,他引:3
建立了HPLC测定伊维菌素微乳中伊维菌素含量的方法。色谱柱为ZirchromC18(4.6mm×250 mm,5μm),流动相为甲醇∶水(85∶15),测定波长为245 nm,流速为1.0 mL/min,柱温为40℃。伊维菌素与辅料及溶剂峰分离良好,在2.22~111.0μg/mL时线性关系良好(R2=0.999 9)。HPLC测定伊维菌素方法便捷、准确、重复性好,可用于伊维菌素微乳含量的测定。 相似文献
2.
为了用高效液相色谱法同时测定复方注射剂中伊维菌素和吡喹酮的含量。采用Hyper-C lone 5u C18柱(250 mm×4.60 mm,5μm),以乙腈-甲醇-水(53∶35∶12)为流动相,流速为1.0mL/m in,检测波长254 nm,柱温30℃的液相检测方法。结果表明,在此色谱条件下,吡喹酮和伊维菌素的分离良好,吡喹酮和伊维菌素分别在30~500μg/mL和5~40μg/mL浓度范围内峰面积与浓度呈良好的线性关系(r2〉0.99)。按外标法以峰面积计算进行测定,吡喹酮和伊维菌素的平均回收率分别为98.93%和95.89%,RSD分别为0.33%和1.58%(n=9)。说明该方法简便、快速、准确,适用于复方吡喹酮注射液中吡喹酮和伊维菌素含量的测定。 相似文献
3.
4.
为了建立伊维菌素吡喹酮咀嚼片同时测定两种主药含量的方法,采用十八烷基硅烷键合硅胶为填充剂,以乙腈∶水的梯度洗脱系统作为流动相,伊维菌素检测波长为245 nm,吡喹酮检测波长为210 nm。在该色谱条件下,溶剂和辅料对伊维菌素和吡喹酮出峰均无干扰,伊维菌素和吡喹酮与相邻杂质峰分离良好。伊维菌素在2~400μg/m L的浓度范围线性关系良好;吡喹酮在1~100μg/m L的浓度范围内线性关系良好。伊维菌素回收率为102.5%,吡喹酮回收率为99.4%。该方法操作简便,准确度高,重复性好,可用于伊维菌素吡喹酮咀嚼片同时测定两种主药的含量。 相似文献
5.
采用高效液相色谱法(HPLC)测定伊维菌素-丙硫苯咪唑片中伊维菌素的含量,结果表明,伊维菌素在20~100μg·mL-1范围内具有良好的线性关系(r=0.9999),平均回收率为99.7%,RSD=0.8%。因此,该法可用于伊维菌素-丙硫苯咪唑片中伊维菌素的含量测定。 相似文献
6.
高效液相色谱法测定赛鸽用复方吡喹酮胶囊中吡喹酮和伊维菌素的含量 总被引:1,自引:1,他引:1
用高效液相色谱法同时测定赛鸽用复方吡喹酮胶囊中吡喹酮和伊维菌素的含量.采用Nova-Pak C18柱(150 mm×3.9 mm,4 μm),以乙腈-甲醇-水(53:35:12)为流动相,流速为1.0 mL/min,检测波长254 nm,柱温25℃.在此色谱条件下,吡喹酮和伊维菌素的分离良好,吡喹酮和伊维菌素分别在511~1 534μg/mL和10.1~30.6μg/mL浓度范围内峰面积与浓度呈良好的线性关系(r>0.999).按外标法以峰面积计算进行测定,吡喹酮和伊维菌素的平均回收率分别为99.9%和98.3%,RSD分别为0.3%和0.6%(n=9).本方法简便、快速、准确,适用于赛鸽用复方吡喹酮胶囊中吡喹酮和伊维菌素含量的测定. 相似文献
7.
用紫外分光光度法测定伊维菌注射液中伊维菌素B1的含量。伊维菌素注射液溶于甲醇,于200~400nm间扫描,在238nm、245nm波长处有最大吸收峰,245nm波长处测定吸伊维菌素作对照品测得伊维菌素注射液的平均回收率为100.06%,RSD为0.24%(n=5),与《中国兽药典》规定方法比较,结果基本一致,且具有快速、准确、易操作等优点。 相似文献
8.
高效液相色谱荧光检测法检测Beagle犬血浆中伊维菌素的试验 总被引:1,自引:0,他引:1
建立一种灵敏、简便、可重复的高效液相色谱检测方法检测Beagle犬血浆中伊维菌素(Ivermectin,IVM)的含量。样品中加入内标多拉菌素(DRM),采用乙腈提取,涡旋振荡后高速离心,上清液于60℃N2吹干,衍生化后进样分析。色谱柱为ODS-2 Hypesil C18(250 mm×4.6 mm,5μm),检测器为荧光检测器,流动相为甲醇-乙腈-0.2%乙酸(55∶43∶2,V/V/V),流速为1 mL/min,激发波长365 nm,发射波长475 nm,柱温为35℃。测得DRM的保留时间为8.9 min,IVM保留时间为10.7 min。在0.25 ng/mL120 ng/mL的范围内,血浆药物浓度与峰面积之比呈良好的线性关系,其线性方程为:y=5.34e-003x+2.86e-003(n=10,R2=0.9998)。120 ng/mL、10 ng/mL、0.25 ng/mL三个浓度的添加回收率为83.01%120 ng/mL的范围内,血浆药物浓度与峰面积之比呈良好的线性关系,其线性方程为:y=5.34e-003x+2.86e-003(n=10,R2=0.9998)。120 ng/mL、10 ng/mL、0.25 ng/mL三个浓度的添加回收率为83.01%91.75%,日内变异系数为3.75%91.75%,日内变异系数为3.75%6.45%,日间变异系数为3.26%6.45%,日间变异系数为3.26%8.86%,最低检测限为0.05 ng/mL。本方法操作简便,灵敏度高,可应用于Beagle犬血浆中伊维菌素的检测。 相似文献
9.
高效液相色谱法测定伊维菌素脂质体药物的含量及包封率 总被引:4,自引:3,他引:1
本试验旨在建立伊维菌素脂质体载体药物含量及包封率测定的高效液相色谱法。Waters surfire C18柱(150 mm×2.1 mm,5 μm),流动相为乙腈—甲醇—水(62∶30∶8),流速1 mL/min,检测波长245 nm,进样量10 μL,柱温30 ℃。采用凝胶过滤法、透析法、冷冻超速离心法、超滤离心法4种方法对脂质体与药物进行分离。结果表明,在优化色谱条件下伊维菌素与辅料及溶剂峰均得到良好分离,伊维菌素在1~50 μg/mL浓度范围内线性关系良好(r=0.9998,n=5),最终采用超速冷冻离心法可将脂质体与药物很好的分离,伊维菌素脂质载体的包封率可达98.54%±1.6%。该方法准确可靠、简单快速,可用于伊维菌素脂质体载体药物含量及包封率的测定。 相似文献
10.
高效液相色谱法测定伊维菌素缔合胶体溶液的含量 总被引:1,自引:1,他引:0
建立了0.3%伊维菌素缔合胶体溶液中伊维菌素含量的HPLC测定方法。采用的流动相为乙腈-甲醇-水(60∶32∶8),检测波长为254 nm。结果表明,伊维菌素H2B1a在6.795-217.4μg/mL浓度范围内线性关系良好(r=0.999 8),平均回收率为99.7%。该方法准确可行,伊维菌素H2B1a与相邻峰分离完全,能排除溶剂和表面活性剂的干扰。 相似文献
11.
In order to establish the determination method of ivermectin (IVM) in the ivermectin microemulsion injection by high performance liquid chromatography (HPLC), Hypersil ODS2 colunm (5 μm,4.6 mm×250 mm) was used in this study. The mobile phase composed of methanol, acetonitrile and water (35:60:5,V/V/V) at a flow rate of 1 mL/min. The detection wave length was set at 244 nm and the column temperature was 30 ℃. The results showed that the HPLC system suitability of IVM was good. A good linear correlation of IVM was observed within the concentration range 80 to 320 μg/mL, and the average recovery rate was 101.90%±2.94% with RSD was 2.88%, the regression equation was Y=22 700X+2 510 (R2=0.9998). The RSD of IVM content in ivermectin microemulsion injection was 1.86%. The method was accurate and reliable,reproducible,easy to operate, which could be used in new type of ivermectin microemulsion injection. The method could be used as the basis of quality control and establishing a quality standard, and to provide basis for quality evaluation, also can provide reliable reference for safe veterinary clinical application in the future. 相似文献
12.
为比较研究制备的伊维菌素长效透皮制剂与普通伊维菌素注射剂药物代谢及药效时间,本研究制备伊维菌素含量分别为0.5%、1.0%和1.5%的长效透皮制剂,采用高效液相色谱法检测不同药量相同体积伊维菌素长效透皮制剂和普通伊维菌素注射剂(1.0%)在家兔体内的药代动力学,并通过PKSolver药代动力学处理软件对数据进行分析。结果显示,0.5%、1.0%、1.5%伊维菌素长效透皮剂和1.0%普通注射剂吸收半衰期分别为0.81、0.52、1.02和0.12 d;达峰时间为1.55、0.97、1.62和0.42 d;峰浓度为47.36、72.02、115.30和99.53 ng/mL;消除半衰期为3.61、5.92、5.59和1.79 d;平均滞留时间为5.27、7.37、5.13和2.16 d;药时曲线面积为1 488.70、3 081.98、3 161.20和480.00 ng·d/mL,伊维菌素长效透皮剂体内维持有效药物浓度的时间长达35 d,普通注射剂仅为9 d。结果表明,伊维菌素长效透皮剂效果稳定,可进行更深入的研究。 相似文献
13.
以BCA为单体材料,采用乳液聚合法制备IVM-PBCA-NP纳米粒,经药物吸附和PVP包被后形成PVP-IVM-PBCA-NP载药纳米粒。经正交试验设计确定以BCA:IVM投量为4:1(g/g),BCA投量为0.4:25(V/V),乳化剂F68浓度为2%,搅拌速度600r/min,反应体系pH值为2、3、6,反应时间3h,为最佳制备条件。在该条件下所制备的PVP-IVM-PBCA-NP药物包封率为(45.43±1.65)%,载药量(9.95±0.23)%,主要粒径为296nm。 相似文献
14.
15.
本试验旨在对伊维菌素微乳制剂进行无菌检查方法学验证和无菌检查试验,确认本试验所用的方法适用于该制剂的无菌检查。按《中国兽药典》2005版一部(附录118)所载"无菌检查法"项下进行试验,通过对阳性对照菌、不同量冲洗液等条件的选择,采用薄膜过滤法对10瓶供试品(每种试验菌的样品量)进行检测,建立了无菌检查方法。经方法验证,用400mL 0.1%蛋白胨水溶液冲洗后,含供试品容器中的7个阳性菌试验组与阳性菌对照组相比均生长良好,说明供试品的该检验量在该检验条件下无抑菌作用或其抑菌作用可以忽略不计,可以用该方法进行供试品的无菌检查。对3批供试品进行无菌检查,阳性对照菌均在24h内生长良好,阴性对照均澄清,无菌生长,3批供试品均澄清,无菌生长,无菌检查试验结果符合规定。 相似文献
16.
XING Shou-ye ZHOU Xu-zheng LI Bing NIU Jian-rong WEI Xiao-juan ZHANG Ji-yu 《中国畜牧兽医》2016,43(1):256-260
The assay was aimed to study the sterility test and validation test of ivermectin microemulsion preparation and establish a sterility test method for ivermectin microemulsion preparation.The test method was carried out according to the method in volumeⅠ, Chinese Veterinary Pharmacopoeia Edition 2005.By choosing positive control bacteria and defining washing volumes in sterility test, the membrane-filter method was used to test the quantity of 10 bottles of test samples, and the sterility test was established.The result of method validation test showed that the test and all of positive control bacteria and microorganism growth after each filter being washed with 400 mL 0.1% peptone solution.It illustrated that the samples had no antimicrobial activity under the sample quantity and test condition.This method was available for sterility test of ivermectin microemulsion preparation.Using this method to test three lots test samples, the results showed that the positive control bacteria grew well within 24 h.The negative control bacteria and three lots test samples were sterile.It indicated that sterility test results met the requirements. 相似文献
17.
联合应用阿苯达唑和伊维菌素在线虫感染鄂尔多斯细毛羊体内的药动学研究 总被引:1,自引:0,他引:1
为阐明联合应用阿苯达唑(ABZ)和伊维菌素(IVM)在胃肠道线虫感染鄂尔多斯细毛羊体内的药动学互作关系,以感染胃肠道线虫的鄂尔多斯细毛羊为研究对象,比较研究了单独或联合应用阿苯达唑和伊维菌素后的药物动力学特征。通过粪便虫卵检查法,选取感染胃肠道线虫的鄂尔多斯细毛羊15只,随机分成3组,每组5只。第1组口服给予阿苯达唑(15mg/kg),第2组皮下注射伊维菌素(0.2mg/kg),第3组皮下注射伊维菌素(0.2mg/kg)的同时口服阿苯达唑(15mg/kg)。于给药后不同时间,由颈静脉采集血样,分离血浆,并用高效液相色谱法测定各时间点血浆阿苯达唑、阿苯达唑亚砜、阿苯达唑砜和伊维菌素浓度,并用PK Solution 2.0药物动力学软件计算出各药动学参数。结果表明,联合用药组绵羊血浆伊维菌素峰浓度(Cmax)、药时曲线下面积(AUC)和平均滞留时间(MRT)分别为44.80ng/mL±6.12ng/mL、5 007.46ng.h/mL±1 301.42ng.h/mL和85.47h±5.03h,均显著(P<0.05)小于单独用药组的对应参数值67.62ng/mL±9.06ng/mL、7 125.08ng.h/mL±908.52ng.h/mL和113.39h±9.00h。口服阿苯达唑组绵羊血浆中仅检测到了阿苯达唑砜和阿苯达唑亚砜,而未检测到阿苯达唑母药。联合用药后,除阿苯达唑砜的达峰时间(T max)显著推迟外,阿苯达唑砜和阿苯达唑亚砜的其他各参数之间均无显著性差异。因此,联合应用IVM和ABZ可影响它们在胃肠道线虫感染鄂尔多斯细毛羊体内的药动学特征,且对伊维菌素药动学特征的影响尤为明显,在临床联合用药过程中应予以重视。 相似文献
18.
伊维菌素脂质体的制备及质量控制研究 总被引:4,自引:0,他引:4
为研究伊维菌素脂质体 ,以卵磷脂和胆固醇为载体 ,采用注入法制备了伊维菌素脂质体 ,并应用紫外倍率系数法测定脂质体中伊维菌素的含量 ,采用高速离心法测定其包封率。结果表明 ,采用注入法制备的伊维菌素脂质体稳定性好 ,大小均匀 ,包封率效果良好 (77.42 %以上 ) ,紫外倍率系数法能消除辅料干扰 ,可作为伊维菌素脂质体质量控制的有效方法 相似文献
19.
AIMS: To determine the plasma disposition and concentrations of ivermectin (IVM) in eggs produced by laying hens following S/C, oral and I/V administration.METHODS: Twenty-four laying hens, aged 37 weeks and weighing 1.73 (SD 0.12) kg were allocated to three groups of eight birds. The injectable formulation of IVM was administered either orally, S/C, or I/V, at a dose of 0.2?mg/kg liveweight, following dilution (1:5, v/v) with propylene glycol. Heparinised blood samples were collected at various times between 0.25 hours and 20 days after drug administration. Eggs produced by hens were also collected daily throughout the study period. Samples of plasma and homogenised egg were analysed using HPLC.RESULTS: Maximum concentrations of IVM in plasma and mean residence time of IVM were lower after oral (10.2 (SD 7.2) ng/mL and 0.38 (SD 0.14) days, respectively) than after S/C (82.9 (SD 12.4) ng/mL and 1.05 (SD 0.24) days, respectively) administration (p<0.01). The time to maximum concentration and elimination half-life were shorter following oral (0.14 (SD 0.04) and 0.23 (SD 0.11) days, respectively) than S/C (0.25 (SD 0.00) and 1.45 (SD 0.45) days, respectively) administration (p<0.01). IVM was first detected in eggs 2 days after treatment in all groups and was detected until 8 days after oral and I/V administration, and until 15 days after S/C administration. Peak concentrations of IVM were 15.7, 23.3 and 1.9?µg/kg, observed 2, 5 and 4 days after I/V, S/C and oral administration, respectively.CONCLUSIONS AND CLINICAL RELEVANCE: The low plasma bioavailability of IVM observed after oral administration in laying hens could result in lower efficacy or subtherapeutic plasma concentrations, which may promote the development of parasitic drug resistance. Due to high IVM residues in eggs compared to the maximum residue limits for other food-producing animal species, a withdrawal period should be necessary for eggs after IVM treatment in laying hens. 相似文献